Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ARWR

Arrowhead Pharmaceuticals Inc

Feb 13 • 04:00PM ET

63.82

+1.44 2.31 %

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: IJH VTI IWM VB VBK VXF XBI IWO MDY IBB

Index	RUT	P/E	41.49	EPS (ttm)	1.54	Insider Own	7.00%	Shs Outstand	137.39M	Perf Week	-1.08%
Market Cap	8.94B	Forward P/E	-	EPS next Y	-4.08	Insider Trans	-5.50%	Shs Float	130.23M	Perf Month	-3.17%
Enterprise Value	8.70B	PEG	-	EPS next Q	-1.04	Inst Own	80.14%	Short Float	8.56%	Perf Quarter	54.08%
Income	202.26M	P/S	8.19	EPS this Y	-32007.08%	Inst Trans	5.75%	Short Ratio	3.48	Perf Half Y	239.83%
Sales	1.09B	P/B	15.43	EPS next Y	-27.19%	ROA	15.45%	Short Interest	11.15M	Perf YTD	-3.87%
Book/sh	4.14	P/C	9.75	EPS next 5Y	-	ROE	65.14%	52W High	76.76 -16.86%	Perf Year	233.96%
Cash/sh	6.55	P/FCF	27.33	EPS past 3/5Y	80.60% 57.10%	ROIC	16.73%	52W Low	9.57 566.88%	Perf 3Y	84.45%
Dividend Est.	-	EV/EBITDA	26.72	Sales past 3/5Y	50.52% 56.63%	Gross Margin	97.70%	Volatility	5.20% 5.86%	Perf 5Y	-27.64%
Dividend TTM	-	EV/Sales	7.98	EPS Y/Y TTM	130.44%	Oper. Margin	27.55%	ATR (14)	3.96	Perf 10Y	1799.40%
Dividend Ex-Date	-	Quick Ratio	3.38	Sales Y/Y TTM	43539.24%	Profit Margin	18.54%	RSI (14)	46.32	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	3.38	EPS Q/Q	115.80%	SMA20	-3.80%	Beta	1.24	Target Price	81.70
Payout	-	Debt/Eq	1.21	Sales Q/Q	10461.32%	SMA50	-4.50%	Rel Volume	0.59	Prev Close	62.38
Employees	711	LT Debt/Eq	1.13	Earnings	Feb 05 AMC	SMA200	77.77%	Avg Volume	3.21M	Price	63.82
IPO	Dec 16, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	491.40% 23.41%	Trades		Volume	1,885,904	Change	2.31%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga)
Feb-07-26 10:40AM	Arrowhead price target lowered to $78 from $81 at Morgan Stanley (TipRanks)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -5.02%
04:54PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results (Business Wire)
Feb-04-26 06:15PM	Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 (PR Newswire) -5.66%
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire) +5.40%
Jan-27-26 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Jan-22-26 03:20AM	Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data (Insider Monkey)
Jan-20-26 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results (Business Wire)
Jan-19-26 05:18PM	Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory (Insider Monkey)
Jan-12-26 05:43PM	Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference (MarketBeat)
Jan-11-26 01:09AM	Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) (Insider Monkey)
Jan-07-26 11:05PM	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants (Business Wire) -7.23%
07:30AM	Loading…
07:30AM	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China (Business Wire)
Jan-06-26 06:14PM	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Business Wire) +10.85%
04:29PM	Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss (Investor's Business Daily)
11:26AM	Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. (Barrons.com)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition (Business Wire)
Jan-05-26 07:30AM	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire) -5.77%
Dec-23-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events (Business Wire)
Dec-15-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.54%
Dec-12-25 08:00AM	Arrowhead price target raised to $80 from $52 at RBC Capital (TipRanks)
Dec-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire) +11.65%
Dec-02-25 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Dec-01-25 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences (Business Wire) +6.74%
Nov-27-25 06:51AM	Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval (Insider Monkey)
Nov-26-25 07:16PM	Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today (Motley Fool) +23.34% -8.68%
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Loading…
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 04:00PM	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire) +5.72%
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +9.42%
Nov-19-25 12:52PM	Arrowhead nets first commercial win as siRNA drug garners FDA approval (Pharmaceutical Technology)
Nov-18-25 11:52AM	Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
07:39AM	RNAi biotech Arrowhead wins first FDA approval (BioPharma Dive)
Nov-06-25 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results (Business Wire)
Nov-04-25 01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences (Business Wire)
Oct-28-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-21-25 07:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis (Business Wire)
Sep-11-25 07:30AM	Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals (Business Wire)
Sep-10-25 11:06AM	NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline (Zacks)
07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire)
12:59AM	H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR) (Insider Monkey)
Sep-05-25 07:44AM	Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal (Motley Fool)
Sep-03-25 04:14PM	Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits (GuruFocus.com) +8.26%
09:42AM	NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy (Zacks)
Sep-02-25 09:53AM	Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion (Investor's Business Daily) +16.57%
08:03AM	Novartis thinks Arrowhead brain drug can succeed where others couldnt (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement (Business Wire)
Aug-27-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences (Business Wire)
Aug-21-25 09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
Aug-20-25 04:41PM	Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform. (Barchart)
Aug-18-25 12:31PM	Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue (Insider Monkey)
Aug-15-25 10:42AM	Stock Market Today: Dow approaches fresh record despite disappointing economic data drop (TheStreet) +9.21%
Aug-14-25 04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily) -6.05%
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +12.30%
04:10PM	Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics (Business Wire)
Aug-07-25 04:10PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results (Business Wire)
09:29AM	Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries (Zacks)
Aug-04-25 11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 06:30AM	Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi (Business Wire)
Jul-31-25 11:58AM	Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal (Insider Monkey)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
Jul-28-25 04:55PM	Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap (Bloomberg)
07:30AM	Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics (Business Wire)
Jul-24-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-23-25 08:00AM	Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics (Business Wire) +6.42%
Jul-22-25 03:40PM	Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns (Insider Monkey)
Jul-21-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results (Business Wire) -12.23%
Jul-17-25 10:58AM	SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots (Zacks)
Jul-16-25 04:01PM	Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label (Business Wire)
Jul-09-25 05:32AM	Arrowhead doses first patient in Phase III trial of zodasiran for HoFH treatment (Clinical Trials Arena) +7.64%
Jul-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia (Business Wire)
Jul-01-25 05:32AM	Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 \| Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth (GlobeNewswire)
Jun-23-25 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran (Business Wire)
Jun-05-25 05:10AM	Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" (Insider Monkey)
Jun-03-25 08:28PM	Lightning Round: Buy Dover right now, says Jim Cramer (CNBC TV)
05:37AM	Arrowhead commences dosing in Phase I/IIa obesity treatment trial (Clinical Trials Arena)
Jun-02-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
May-29-25 07:30AM	Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences (Business Wire) +8.10%
May-13-25 03:07AM	Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... (GuruFocus.com) +9.38%
May-12-25 04:10PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance) +7.21%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results (Business Wire)
May-07-25 02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
12:14PM	Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (Seeking Alpha)
08:31AM	SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences (Business Wire)
May-05-25 07:49AM	Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-30-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results (Business Wire)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-15-25 04:00PM	Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer (Business Wire) -11.81%
Apr-04-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -11.44%

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Brien Patrick	COO	Jan 05 '26	Sale	63.11	49,493	3,123,349	474,908	Jan 05 09:50 PM
Hamilton James C	Chief Medical Officer	Jan 05 '26	Sale	63.11	40,164	2,534,661	171,958	Jan 05 09:41 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '26	Sale	66.10	13,187	871,703	3,792,739	Jan 05 09:39 PM
James Hamilton	Officer	Jan 05 '26	Proposed Sale	63.09	39,728	2,506,627		Jan 05 04:59 PM
Patrick O'Brien	Officer	Jan 05 '26	Proposed Sale	63.10	49,493	3,123,172		Jan 05 04:58 PM
Christopher Anzalone	Officer	Jan 02 '26	Proposed Sale	66.10	13,187	871,668		Jan 02 04:04 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Option Exercise	6.15	51,726	318,115	3,857,652	Dec 30 05:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Sale	69.13	51,726	3,575,575	3,805,926	Dec 30 05:46 PM
Ferrari Mauro	Director	Dec 26 '25	Sale	70.00	7,530	527,100	69,053	Dec 30 05:46 PM
Christopher Anzalone	Officer	Dec 29 '25	Proposed Sale	69.13	51,726	3,575,575		Dec 29 04:23 PM
Mauro Ferrari	Director	Dec 26 '25	Proposed Sale	70.00	7,530	527,070		Dec 29 04:03 PM
Waddill William D.	Director	Dec 19 '25	Sale	67.65	8,367	566,038	56,563	Dec 23 06:01 PM
Vakiener Victoria	Director	Dec 19 '25	Sale	67.68	10,040	679,491	35,723	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 19 '25	Sale	67.66	13,445	909,683	3,818,512	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 22 '25	Sale	68.44	12,586	861,340	3,805,926	Dec 23 06:01 PM
OLUKOTUN ADEOYE Y	Director	Dec 19 '25	Sale	67.66	10,000	676,623	33,600	Dec 23 06:01 PM
Christopher Anzalone	Officer	Dec 22 '25	Proposed Sale	68.43	12,586	861,319		Dec 22 04:00 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 17 '25	Sale	64.04	85,000	5,443,462	3,831,957	Dec 19 06:56 PM
Christopher Anzalone	Officer	Dec 19 '25	Proposed Sale	67.66	13,445	909,632		Dec 19 04:08 PM
William Waddill	Director	Dec 19 '25	Proposed Sale	67.65	8,367	566,001		Dec 19 04:07 PM
Adeoye Olukotun	Director	Dec 19 '25	Proposed Sale	67.66	10,000	676,589		Dec 19 04:07 PM
Victoria Vakiener	Director	Dec 19 '25	Proposed Sale	67.68	10,040	679,464		Dec 19 04:06 PM
Christopher Anzalone	Officer	Dec 17 '25	Proposed Sale	64.04	85,000	5,443,253		Dec 17 05:11 PM
Christopher Anzalone	Officer	Dec 16 '25	Proposed Sale	62.58	54,298	3,398,142		Dec 16 04:47 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 15 '25	Sale	68.85	130,000	8,950,615	3,971,255	Dec 16 01:14 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 16 '25	Sale	62.58	54,298	3,398,187	3,916,957	Dec 16 01:14 PM
Christopher Anzalone	Officer	Dec 15 '25	Proposed Sale	68.85	130,000	8,950,580		Dec 15 04:50 PM
PERRY MICHAEL S	Director	Dec 05 '25	Sale	61.03	16,250	991,738	115,240	Dec 09 06:04 PM
Michael Perry	Director	Dec 05 '25	Proposed Sale	60.99	16,250	991,129		Dec 05 04:00 PM
Ferrari Mauro	Director	Nov 28 '25	Sale	56.39	8,750	493,412	68,764	Dec 01 06:10 PM
Mauro Ferrari	Director	Nov 28 '25	Proposed Sale	56.35	8,750	493,062		Nov 28 01:19 PM
Hamilton James C	Chief Medical Officer	Oct 01 '25	Sale	35.00	20,000	700,000	212,122	Oct 03 06:15 PM
James Hamilton	Officer	Oct 01 '25	Proposed Sale	35.00	20,000	700,015		Oct 01 03:44 PM
Hamilton James C	Chief Medical Officer	Sep 12 '25	Sale	30.00	15,000	450,000	232,122	Sep 16 06:06 PM
Hamilton James C	Officer	Sep 12 '25	Proposed Sale	30.00	15,000	449,970		Sep 12 04:33 PM
Hamilton James C	Chief Medical Officer	Sep 02 '25	Sale	25.00	15,000	375,000	247,122	Sep 04 05:37 PM
Hamilton James C	Officer	Sep 02 '25	Proposed Sale	25.00	15,000	374,970		Sep 02 05:12 PM
Hamilton James C	Chief Medical Officer	Aug 15 '25	Sale	20.00	9,389	187,780	262,122	Aug 15 05:59 PM
Hamilton James C	Chief Medical Officer	Aug 13 '25	Sale	20.00	611	12,220	271,511	Aug 15 05:59 PM
Hamilton James C	Officer	Aug 15 '25	Proposed Sale	20.00	9,389	187,750		Aug 15 03:42 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Hamilton James C	Officer	Aug 13 '25	Proposed Sale	19.95	611	12,190		Aug 13 05:57 PM
Myszkowski Kenneth Allen	Officer	Jul 10 '25	Proposed Sale	19.04	40,000	761,709		Jul 10 04:30 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 11 '25	Sale	11.49	50,800	583,692	3,921,255	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 10 '25	Sale	10.87	50,000	543,500	3,972,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 09 '25	Sale	10.07	40,322	406,145	4,022,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Officer	Apr 11 '25	Proposed Sale	11.49	50,800	583,751		Apr 11 04:29 PM
Anzalone Christopher Richard	Officer	Apr 10 '25	Proposed Sale	10.86	50,000	543,215		Apr 10 04:35 PM
Anzalone Christopher Richard	Officer	Apr 09 '25	Proposed Sale	10.07	40,322	406,057		Apr 09 04:44 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 13 '25	Sale	15.07	51,425	774,975	4,062,377	Mar 17 05:45 PM
Anzalone Christopher Richard	Officer	Mar 13 '25	Proposed Sale	15.07	51,425	774,785		Mar 13 04:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Option Exercise	7.75	166,667	1,291,669	3,940,469	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Option Exercise	7.75	133,333	1,033,331	4,073,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Sale	18.03	166,667	3,005,006	3,907,135	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Sale	17.02	133,333	2,269,328	3,773,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Officer	Mar 04 '25	Proposed Sale	17.02	133,333	2,268,742		Mar 04 05:48 PM
Anzalone Christopher Richard	Officer	Mar 03 '25	Proposed Sale	18.03	166,667	3,004,203		Mar 03 05:09 PM

Open in Screener

PTGX

Protagonist Therapeutics Inc

Feb 13 • 04:00PM ET

81.49

-0.44 -0.54 %

Healthcare • Biotechnology • USA • NASD

PTGX Protagonist Therapeutics Inc daily Stock Chart

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR VTI IWM XBI VB VXF SPSM IJT IWO IBB

Index	RUT	P/E	128.65	EPS (ttm)	0.63	Insider Own	5.63%	Shs Outstand	62.45M	Perf Week	-3.55%
Market Cap	5.09B	Forward P/E	55.97	EPS next Y	1.46	Insider Trans	-5.70%	Shs Float	58.99M	Perf Month	-4.39%
Enterprise Value	4.53B	PEG	-	EPS next Q	-0.33	Inst Own	117.94%	Short Float	13.79%	Perf Quarter	-3.96%
Income	45.91M	P/S	24.35	EPS this Y	-139.20%	Inst Trans	4.22%	Short Ratio	9.49	Perf Half Y	48.19%
Sales	209.22M	P/B	7.88	EPS next Y	187.81%	ROA	7.03%	Short Interest	8.13M	Perf YTD	-6.70%
Book/sh	10.34	P/C	8.84	EPS next 5Y	-	ROE	7.80%	52W High	96.54 -15.59%	Perf Year	110.68%
Cash/sh	9.22	P/FCF	79.96	EPS past 3/5Y	- -	ROIC	7.02%	52W Low	33.70 141.81%	Perf 3Y	408.04%
Dividend Est.	-	EV/EBITDA	220.71	Sales past 3/5Y	151.35% 351.71%	Gross Margin	99.28%	Volatility	3.54% 4.24%	Perf 5Y	211.74%
Dividend TTM	-	EV/Sales	21.65	EPS Y/Y TTM	-72.97%	Oper. Margin	9.09%	ATR (14)	3.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.05	Sales Y/Y TTM	-35.39%	Profit Margin	21.94%	RSI (14)	45.20	Recom	1.23
Dividend Gr. 3/5Y	- -	Current Ratio	13.05	EPS Q/Q	-14.73%	SMA20	-1.65%	Beta	2.25	Target Price	101.08
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	0.79%	SMA50	-4.57%	Rel Volume	0.50	Prev Close	81.93
Employees	126	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	21.28%	Avg Volume	857.28K	Price	81.49
IPO	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.10% 31.51%	Trades		Volume	428,353	Change	-0.54%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Barclays	Overweight	$72
Sep-12-25	Initiated	Leerink Partners	Outperform	$73
Jun-17-25	Initiated	Citigroup	Buy	$72
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33

Show Previous Ratings

Feb-11-26 03:13PM	H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy (Insider Monkey)
Jan-07-26 07:30AM	Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 (ACCESSWIRE)
Jan-06-26 04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
09:30AM	Loading…
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
Dec-05-25 04:21PM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
Nov-27-25 03:45AM	Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice (ACCESSWIRE)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 04:05PM	Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting (ACCESSWIRE)
Oct-30-25 10:00AM	Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:40AM	Loading…
Oct-28-25 07:40AM	Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 07:35AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences (ACCESSWIRE)
Oct-18-25 12:04PM	Johnson & Johnson's M&A Strategy Is the Real Story for Investors (MarketBeat)
Oct-13-25 02:50PM	Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal (Zacks) -9.00%
06:46AM	J&J in talks to acquire Protagonist Therapeutics (Pharmaceutical Technology)
Oct-10-25 07:07PM	Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today (Motley Fool) +29.77%
02:21PM	Trump's China tariff threat sinks stocks, Applied Digital surges (Yahoo Finance Video)
01:38PM	RTW Investments' Rod Wong: Expect more deals in biotech space (CNBC TV)
11:53AM	Protagonist Therapeutics stock surges after J&J acquisition talks report (Investing.com)
11:23AM	Protagonist Stock Surges on Johnson & Johnson Report (The Wall Street Journal)
11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
10:23AM	Stock Market Today: Market Tumbles After Trump Threatens "Massive Increase" on China Tariffs (TheStreet)
Oct-07-25 08:10AM	Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill (ACCESSWIRE)
Sep-17-25 11:45AM	Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory (Insider Monkey)
08:00AM	Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress (ACCESSWIRE)
10:45AM	Loading…
Sep-15-25 10:45AM	Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 (ACCESSWIRE)
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Sep-11-25 08:00AM	Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency (ACCESSWIRE)
Aug-26-25 04:05PM	Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 (ACCESSWIRE) +7.79%
Aug-25-25 07:00AM	Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera (ACCESSWIRE)
Aug-06-25 05:25PM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:24PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-22-25 11:51AM	JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Jul-21-25 08:05AM	Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis (ACCESSWIRE)
Jun-30-25 04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily) -9.16%
04:05PM	Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity (ACCESSWIRE)
Jun-26-25 07:05AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate (ACCESSWIRE)
Jun-24-25 03:09PM	Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera (Insider Monkey)
Jun-23-25 01:17PM	Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains? (Zacks)
09:07AM	Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? (Zacks)
Jun-17-25 12:57PM	Citi initiates coverage on biotech amid improving sentiment in sector (Investing.com)
Jun-09-25 10:00AM	For Patients With Rare Blood Cancer, New Drug Offers Relief (The Wall Street Journal)
Jun-01-25 08:00AM	Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera (Business Wire)
May-27-25 09:29AM	Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome (Insider Monkey)
May-21-25 07:05AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 (ACCESSWIRE)
May-12-25 08:11AM	J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study (Zacks) +5.35%
May-09-25 10:27AM	Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
08:05AM	Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting (ACCESSWIRE)
May-06-25 06:30PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.13%
04:05PM	Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-23-25 10:35AM	Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 (ACCESSWIRE)
Apr-10-25 08:10AM	Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill (ACCESSWIRE)
Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-25-25 09:55AM	Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (Zacks)
Mar-18-25 02:10PM	Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) Best Biotech Stock for 2025? (Insider Monkey)
07:00AM	These 10 biotech companies are changing how we discover new drugs and treat complex diseases (FastCompany)
07:00AM	Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 (ACCESSWIRE)
Mar-15-25 04:40PM	Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why (Zacks)
Mar-11-25 09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com) +6.81%
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
06:47AM	Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday (Insider Monkey)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily) +45.89%
08:15AM	Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis (ACCESSWIRE)
Mar-08-25 09:15AM	Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis (ACCESSWIRE)
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-21-25 08:35AM	Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:34AM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-12-25 07:51AM	Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Jan-29-25 06:15PM	Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025 (ACCESSWIRE)
Jan-06-25 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Dec-19-24 04:05PM	Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 (ACCESSWIRE)
Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waddill William D.	Director	Feb 06 '26	Option Exercise	8.31	20,000	166,200	27,825	Feb 06 04:38 PM
Waddill William D.	Director	Feb 06 '26	Sale	83.68	20,000	1,673,600	7,825	Feb 06 04:38 PM
WILLIAM D WADDILL	Director	Feb 06 '26	Proposed Sale	83.68	20,000	1,673,672		Feb 06 04:04 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Option Exercise	14.12	24,890	351,528	588,710	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Option Exercise	21.58	4,068	87,787	578,573	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Option Exercise	4.21	19,315	81,316	593,820	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 26 '26	Sale	84.03	24,890	2,091,470	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 23 '26	Sale	84.59	19,315	1,633,856	574,505	Jan 27 09:21 PM
PATEL DINESH V PH D	President and CEO	Jan 27 '26	Sale	83.19	4,068	338,417	574,505	Jan 27 09:21 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Option Exercise	16.18	28,000	453,080	106,523	Jan 27 09:20 PM
Ali Asif	Chief Financial Officer	Jan 27 '26	Sale	83.13	46,203	3,841,037	60,320	Jan 27 09:20 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Option Exercise	8.04	5,000	40,200	89,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 23 '26	Sale	82.42	13,151	1,083,905	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 26 '26	Sale	82.28	5,000	411,400	84,115	Jan 27 09:19 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 27 '26	Sale	82.00	5,000	410,000	84,115	Jan 27 09:19 PM
ASIF ALI	Officer	Jan 27 '26	Proposed Sale	83.14	46,203	3,841,128		Jan 27 05:12 PM
ARTURO MOLINA	Officer	Jan 27 '26	Proposed Sale	82.00	5,000	410,000		Jan 27 04:01 PM
ARTURO MOLINA	Officer	Jan 26 '26	Proposed Sale	82.28	5,000	411,396		Jan 26 04:29 PM
ARTURO MOLINA	Officer	Jan 23 '26	Proposed Sale	83.42	13,151	1,097,116		Jan 23 04:32 PM
Dinesh Patel	CEO	Jan 23 '26	Proposed Sale	84.62	108,273	9,162,061		Jan 23 04:06 PM
MOLINA ARTURO MD	Chief Medical Officer	Jan 20 '26	Sale	82.48	9,514	784,715	97,266	Jan 21 05:17 PM
PATEL DINESH V PH D	President and CEO	Jan 20 '26	Sale	82.48	34,438	2,840,446	580,505	Jan 21 05:16 PM
Ali Asif	Chief Financial Officer	Jan 20 '26	Sale	82.48	8,588	708,338	78,077	Jan 21 05:15 PM
ARTURO MOLINA MD	Officer	Jan 20 '26	Proposed Sale	82.48	9,514	784,715		Jan 21 05:12 PM
DINESH V PATEL PH D	Officer, Director	Jan 20 '26	Proposed Sale	82.48	34,438	2,840,446		Jan 21 05:11 PM
Asif Ali	Officer	Jan 20 '26	Proposed Sale	82.48	8,588	708,338		Jan 21 05:10 PM
SELICK HAROLD E	Director	Jan 09 '26	Option Exercise	4.21	14,299	60,199	60,845	Jan 13 04:45 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 17 '25	Sale	84.77	2,712	229,896	81,180	Nov 19 04:01 PM
Waddill William D.	Director	Oct 10 '25	Option Exercise	6.98	12,000	83,760	17,130	Oct 14 04:01 PM
Waddill William D.	Director	Oct 10 '25	Sale	81.62	12,000	979,480	5,130	Oct 14 04:01 PM
WILLIAM WADDILL	Director	Oct 10 '25	Proposed Sale	67.04	12,000	804,480		Oct 10 04:18 PM
Waddill William D.	Director	Sep 22 '25	Sale	64.25	4,000	257,000	5,130	Sep 24 08:35 PM
WILLIAM WADDILL	Director	Sep 22 '25	Proposed Sale	62.20	4,000	248,800		Sep 22 04:27 PM
Waddill William D.	Director	Aug 27 '25	Sale	59.25	4,000	237,000	9,130	Aug 29 05:30 PM
WILLIAM WADDILL	Director	Aug 27 '25	Proposed Sale	56.99	4,000	227,960		Aug 27 04:33 PM
PATEL DINESH V PH D	President and CEO	Jul 25 '25	Sale	54.78	10,415	570,534	520,603	Jul 28 06:08 PM
PATEL DINESH V PH D	President and CEO	Jul 22 '25	Sale	55.05	22,065	1,214,678	548,538	Jul 23 06:57 PM
PATEL DINESH V PH D	President and CEO	Jul 23 '25	Sale	54.79	17,520	959,921	531,018	Jul 23 06:57 PM
PATEL DINESH V PH D	President and CEO	Jul 21 '25	Sale	54.86	12,859	705,445	570,603	Jul 23 06:57 PM
Dinesh Patel	CEO	Jul 22 '25	Proposed Sale	55.22	50,000	2,761,000		Jul 22 04:04 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 09 '25	Option Exercise	8.04	10,000	80,400	93,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 10 '25	Option Exercise	8.04	10,000	80,400	93,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 10 '25	Sale	57.03	10,000	570,300	83,892	Jun 11 05:40 PM
MOLINA ARTURO MD	Chief Medical Officer	Jun 09 '25	Sale	55.51	10,000	555,100	83,892	Jun 11 05:40 PM
ARTURO MOLINA	Officer	Jun 10 '25	Proposed Sale	57.03	10,000	570,269		Jun 10 05:51 PM
ARTURO MOLINA	Officer	Jun 09 '25	Proposed Sale	55.51	10,000	555,077		Jun 09 04:46 PM
SELICK HAROLD E	Director	Apr 28 '25	Option Exercise	1.16	10,725	12,441	43,851	Apr 30 04:45 PM
Ali Asif	Chief Financial Officer	Apr 22 '25	Sale	46.00	1,756	80,776	61,065	Apr 23 04:30 PM
Waddill William D.	Director	Mar 17 '25	Sale	54.25	4,000	217,000	13,130	Mar 19 04:01 PM
WILLIAM D WADDILL	Director	Mar 17 '25	Proposed Sale	54.78	4,000	219,120		Mar 17 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Option Exercise	24.48	30,514	746,956	114,406	Mar 14 06:21 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Sale	55.74	30,514	1,700,850	83,892	Mar 14 06:21 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Option Exercise	14.90	24,903	371,164	87,724	Mar 14 06:20 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Sale	58.73	24,903	1,462,553	62,821	Mar 14 06:20 PM
MOLINA ARTURO MD	Officer	Mar 13 '25	Proposed Sale	55.00	30,514	1,678,270		Mar 13 05:24 PM
Ali Asif	Officer	Mar 12 '25	Proposed Sale	58.73	24,903	1,462,587		Mar 12 05:31 PM
PATEL DINESH V PH D	President and CEO	Mar 05 '25	Option Exercise	4.21	24,000	101,040	564,260	Mar 05 08:02 PM
PATEL DINESH V PH D	President and CEO	Feb 19 '25	Sale	38.18	5,359	204,607	540,260	Feb 20 05:25 PM

ARWR

Arrowhead Pharmaceuticals Inc

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience